Please login to the form below

Not currently logged in
Email:
Password:

Valchlor

This page shows the latest Valchlor news and features for those working in and with pharma, biotech and healthcare.

EU nod for Actelion's skin cancer drug Ledaga

EU nod for Actelion's skin cancer drug Ledaga

The Swiss biotech - which already sells Ledaga (mechlorethamine or chlormethine) under the Valchlor brand in the US - notes that the European Commission cleared the drug as a topical treatment for mycosis ... Actelion acquired Valchlor in 2013 when it

Latest news

  • Actelion partners with PatientsLikeMe on blood cancer research Actelion partners with PatientsLikeMe on blood cancer research

    Mitchell Nagao, Actelion's senior director - medical head of Valchlor and Zavesca, said: “As changes in technology, culture, and treatment affect how patients live with disease, we want measurement to evolve

  • Actelion complete Ceptaris purchase Actelion complete Ceptaris purchase

    light to Valchlor (mechlorethamine hydrochloride) as a treatment for patients with early-stage mycosis fungoides-type cutaneous T-cell lymphoma (CTL). ... Such preparations do not undergo the same rigorous FDA review as Valchlor," he added.

  • Actelion to buy Ceptaris - if FDA backs its cancer treatment Actelion to buy Ceptaris - if FDA backs its cancer treatment

    Acquisition contingent on Valchlor approval in rare lymphoma. Actelion is set to acquire US-based biopharma Ceptaris, but only if US regulators approve Ceptaris' cancer treatment Valchlor. ... Valchlor is also under review in Europe where it is also

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics